Seagen acquisition will give Pfizer 'anchor asset' that Wall Street desires: CEO Bourla
has been actively dealmaking and receiving FDA approvals for new products and new indications in the past couple of years, but that has all been overshadowed by its runaway success with COVID-19 products resulting in tens of billions of dollars in revenue in the past few years. The company…
#fda #jpmorgan #pfizer #albertbourla #seagen #adctechnology #yahoofinance #mylotarg #holds #anjaleekhemlani